Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.44 |
| ▸ | YTHDC1 | Q96MU7 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 7/20 | 0.44 |
| ▸ | CCNK | O75909 | 2/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17628618 | 0.75 | CDK1 (0.57) | ADORA3ADORA1CDK1YTHDC1CTSL | |
| SCHEMBL17450113 | 0.74 | CDK1 (0.56) | CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL17450137 | 0.73 | APP (0.58) | ADORA3ADORA1CDK1 | |
| SCHEMBL17628574 | 0.72 | CDK1 (0.76) | ADORA3ADORA1CDK1YTHDC1CCNE2 | |
| SCHEMBL3306416 | 0.71 | CDK2 (0.64) | ADORA3ADORA1CDK1CTSLCCNK | |
| SCHEMBL17450131 | 0.71 | CTSL (0.72) | CDK1YTHDC1CTSLCDK2HDAC1 | |
| SCHEMBL3299543 | 0.70 | CDK2 (0.70) | CDK1CCNE1CDK2 | |
| SCHEMBL20119336 | 0.69 | HTT (0.52) | ADORA3ADORA1CDK1YTHDC1CTSL | |
| SCHEMBL3859252 | 0.68 | CDK1 (0.78) | CDK1CCNE1CDK2 | |
| SCHEMBL17802614 | 0.68 | CTSL (0.75) | CDK1YTHDC1CTSLCCNE2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10519160-B2 | Imaging agents for neural flux | THE GENERAL HOSPITAL CORPORATION (US) | 2019-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519160-B2 | Imaging agents for neural flux | SLC18A2, SLC18A3, PMP22 | ADORA3 855/4885ADORA1 910/4885CDK1 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.